Introduction {#s1}
============

In 2011, it is estimated that 39,870 new cases of rectal cancer will occur in the United states. In the same year, an estimated 49,380 people will die from rectal and colon cancer comined [@pone.0045388-Siegel1]. Today the increasing use of neoadjuvant radiation-based therapy(it is mostly RT and CRT) and improvements in the quality of rectal cancer surgery, particularly the standardisation of total mesorectal excision (TME), the combination of this strategies is recommended as a standard procedure for treatment of locally advanced rectal cancer[@pone.0045388-Kapiteijn1]--[@pone.0045388-Wong1]. However, despite generally high response rates, a small proportion of patients fail to respond to neoadjuvant radiation-basedtherapy, or even progress during therapy. There is now substantial evidence that biological markers may be useful for identifying those patients who would benefit from neoadjuvant therapy [@pone.0045388-Cuddihy1].

To date, p53 is the most studied response predictor in rectal cancer [@pone.0045388-Huerta1]. It is a master gene in the stress response that plays an important role in cancer development. The p53 tumour suppressor gene is the most widely mutated gene in human tumorigenesis, with mutations occurring in at least 50% of human cancers [@pone.0045388-Tewari1]. p53 encodes a transcriptional activator whose targets may include genes that regulate genomic stability, the cellular response to DNA damage, and cell-cycle progression [@pone.0045388-Vousden1]. Preclinical studies have shown that wild-type p53 was required for radiation-induced cell death in mouse thymocytes [@pone.0045388-Lowe1]. Thymocytes carried p53-homozygous mutants could resistant to 5.0 Gy, and p53 heterozygous thymocytes were relatively resistant to the same dose of radiation; while wild-type p53 cells were highly sensitive to the same dose of radiation [@pone.0045388-Lowe1]. These results have been confirmed in models of colorectal cancer *in vitro* and *in vivo* [@pone.0045388-Merritt1], [@pone.0045388-Spitz1].

The use of p53 status as a biological marker to predict the response of rectal cancer to neoadjuvant therapy, however, is disappointing, and the findings to date have shown conflicting results [@pone.0045388-Huerta1], [@pone.0045388-Shinto1]--[@pone.0045388-Brophy1]. Several studies found that patients with wild-type form of p53 often had better responses to therapy than those with mutation p53 [@pone.0045388-Chen2]--[@pone.0045388-Fu1]. Other studies, however, evaluated p53 status in rectal cancer patients and drew different conclusions [@pone.0045388-Shinto1]--[@pone.0045388-Brophy1]. These conflicting results may be attributable to the limited detection power inherent in studies that test small subsets of patients. We therefore performed a meta-analysis of the value of p53 status for predicting response to neoadjuvant radiation-based therapy in rectal cancer.

10.1371/journal.pone.0045388.t001

###### TRG classification and standard definition.
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  TRG classification                                                                                           standard definition               
  ----------------------------------------------------------------------------------------------------------- --------------------- ------------ ---------
  Residual tumor rate (%)                                                                                             ≥75%             \<50%        0%
  Dworak or Rodel [@pone.0045388-Dworak1], [@pone.0045388-Rodel1]                                                  Grade 0--1        Grade 3--4   Grade 4
  Mandard [@pone.0045388-Mandard1]                                                                                  TRG 4--5          TRG 1--2     TRG 1
  AJCC [@pone.0045388-Edge1]                                                                                          TRG 3           TRG 0--2     TRG 0
  JSCCR [@pone.0045388-JapaneseSocietyforCanceroftheColonandRectum1]                                                TRG 0--1          TRG 2--3     TRG 3
  Lowe [@pone.0045388-Lowe1]                                                                                            1               3--4         4
  Elsaleh [@pone.0045388-Elsaleh1], Kandioler [@pone.0045388-Kandioler1] and Kelley [@pone.0045388-Kelley1]           NR/SD            CR+PR        CR
  Scott [@pone.0045388-Scott1]                                                                                         SD              CR+PR1       CR
  RCRG staging [@pone.0045388-Wheeler1]                                                                             RCRG 2--3          RCRG 1       --

NR:no response; SD: stable disease; CR: complete response; PR: partial response.

Materials and Methods {#s2}
=====================

Publication Search {#s2a}
------------------

PubMed, Embase, and Web of Science databases were searched (up to May 8, 2012) using the search terms: 'TP53', 'p53', 'p53 protein', 'p53 mutation', '17p13 gene', and 'rectal cancer'. All potentially eligible studies were retrieved and their bibliographies were carefully scanned to identify other eligible studies. Additional studies were identified by a hand search of the references cited in the original studies. When multiple studies of the same patient population were identified, we included the published report with the largest sample size. Only studies published in English were included in this meta-analysis.

![Improving the quality of reports of meta-analyses of randomized controlled trials; the Quality of Reporting of Meta-Analyses (QUOROM) statement flow diagram.](pone.0045388.g001){#pone-0045388-g001}
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###### Characteristics of studies included in the meta-analysis.
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  Author                                                         Year     Country      N    Neoadjuvanttreatment   Detection   P53(%)[\*](#nt103){ref-type="table-fn"}   Original TRGclassification   Provided information on pathologic response               
  ------------------------------------------------------------- ------ ------------- ----- ---------------------- ----------- ----------------------------------------- ---------------------------- --------------------------------------------- ------------ ---------
  Shinto [@pone.0045388-Shinto1]                                 2011     Janpan      96            CRT             protein                      63%                               Dworak                                 --                         TRG 3--4      --
                                                                                                                                                                                   JSCCR                               TRG 0--1                         --         --
  Chen [@pone.0045388-Chen1]                                     2011       USA       96            CRT              gene                        54%                                AJCC                                 TRG 3                       TRG 0--1     TRG 0
  Garcia [@pone.0045388-Garcia1]                                 2011      Spain      80            CRT             protein                      61%                               Rodel                               grade 0/1                    grade 3--4   grade 4
  Chen [@pone.0045388-Chen2]                                     2010      China      58            CRT             protein                      40%                              CR/PR/NR                                NR                          CR+PR        --
  Brophy [@pone.0045388-Brophy1]                                 2009     Ireland     69            CRT             protein                      50%                              Mandard                              TRG 4--5                      TRG 1--2     TRG 1
  Moral [@pone.0045388-Moral1]                                   2009      Spain      39            CRT             protein                      54%                                 --                               No response                       --         --
  Jakob [@pone.0045388-Jakob1]                                   2008     Germany     22            CRT             protein                      59%                               Dworak                              TRG 0--1                         --         --
  Zlobec [@pone.0045388-Zlobec1]                                 2008   Switzerland   92         RT or CRT          protein                      37%                              CR/PR/NR                                --                            CR         CR
  Negri [@pone.0045388-Negri1]                                   2008      Italy      57         RT or CRT          protein                      77%                              CR/PR/NR                            No response                     CR+PR        --
  Terzi [@pone.0045388-Terzi1]                                   2007     Turkey      37            CRT             protein                      84%                               Dworak                              TRG 0--1                      TRG 3--4      --
  Kobayashi [@pone.0045388-Kobayashi1]                           2007      Japan      52            CRT             protein                      63%                               Rodel                                  --                         TRG 3--4   
  Takeuchi [@pone.0045388-Takeuchi1]                             2007      Japan      24            HRT             protein                      63%                               JSCCR                              grade 0--1                    grade 2--3     --
  Sadahiro [@pone.0045388-Sadahiro1]                             2007      Japan      96         RT or CRT          protein                      61%                              Mandard                              TRG 4--5                         --         --
  Lopez-Crapez [@pone.0045388-LopezCrapez1]                      2005     France      70         RT or CRT           gene                        50%                            RCRG staging                           RCRG 2--3                      RCRG 1       --
  Lopez-Crapez [@pone.0045388-LopezCrapez1]                      2005     France      70         RT or CRT          protein                      56%                            RCRG staging                           RCRG 2--3                      RCRG 1       --
  Komuro [@pone.0045388-Komuro1]                                 2005      Japan      96             RT             protein                      49%                               JSCCR                              grade 0--1                    grade 2--3     --
  Kelley [@pone.0045388-Kelley1]                                 2005       USA       50            CRT             protein                      62%                              CR/PR/NR                                NR                          CR+PR        CR
  Suzuki [@pone.0045388-Suzuki1]                                 2004      Japan      93            CRT             protein                      54%                               JSCCR                              grade 0--1                    grade 2--3     --
  Suzuki [@pone.0045388-Suzuki1]                                 2004      Japan      93            CRT             protein                      54%                              Mandard                              TRG 4--5                         --         --
  Charara [@pone.0045388-Charara1]                               2004       USA       47            CRT             protein                      45%                              CR/PR/NR                                --                            CR         CR
  Diez [@pone.0045388-Diez1]                                     2003      Spain      73             RT             protein                      73%                                Lowe                                   1                           3--4         4
  Saw [@pone.0045388-Saw1]                                       2003    Australia    58         RT or CRT           gene                        43%                              Mandard                                 --                         TRG 1--2      --
  Komuro [@pone.0045388-Komuro2]                                 2003      Japan      111            RT             protein                      49%                               JSCCR                              grade 0--1                    grade 2--3     --
  Rebischung [@pone.0045388-Rebischung1]                         2002     France      86             RT              gene                        51%                              CR/PR/NR                            No response                                  CR
  Kandioler [@pone.0045388-Kandioler1]                           2002     Austria     64             RT              gene                        45%                              CR/PR/SD                                SD                          CR+PR        CR
  Rodel [@pone.0045388-Rodel2]                                   2002     Germany     44            CRT             protein                      45%                               Rodel                                  --                        grade 3--4     --
  Nasierowska-Guttmejer [@pone.0045388-NasierowskaGuttmejer1]    2001     Poland      27            CRT             protein                      54%                           CR/PR1/PR2/SD                              SD                          CR+PR1       CR
  Elsaleh [@pone.0045388-Elsaleh1]                               2000    Australia    48            CRT              gene                        35%                              CR/PR/SD                                --                          CR+PR        --
  Elsaleh [@pone.0045388-Elsaleh1]                               2000    Australia    48            CRT             protein                      40%                              CR/PR/SD                                --                          CR+PR        --
  Sakakura [@pone.0045388-Sakakura1]                             1998      Japan      28            HCRT             gene                        50%                               Rodel                                grade 1                     grade 3--4     --
  Luna-Perez [@pone.0045388-LunaPerez1]                          1998     Mexico      26            CRT             protein                      54%                        Residual tumor rate                          ≥75%                         \<50%        0%
  Fu [@pone.0045388-Fu1]                                         1998      Japan      49             RT             protein                      49%                               JSCCR                              grade 0--1                    grade 2--3  
  Spitz [@pone.0045388-Spitz2]                                   1997       USA       42            RCT             protein                      55%                                Lowe                                   1                           3--4         4

Hyperthermoradiation:HRT; hyperthermochemoradiotherapy:HCRT; N: number of patients analyzed;

over expression of TP53 protein and/or TP53 gene mutation frequency(%); −:data not reported.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Studies included in this meta-analysis had to meet all of the following criteria: (a) evaluation of p53 status for predicting the response to neoadjuvant radiation-based therapy in early-stage rectal cancer, locally-advanced rectal cancer, (b) described therapeutic pathological response, (c) retrospective or prospective cohort study, (d) inclusion of adequate data to allow the estimation of a risk ratio (RR) with 95% confidence intervals (95% CI), and (e) studies published in English. Reviews, letters to the editor, and articles published in books were excluded.

![Forest plots of RR were assessed for association between p53 and good response among rectal cancer patients treated with neoadjuvant radiation-based therapy.](pone.0045388.g002){#pone-0045388-g002}

![Forest plots of RR were assessed for association between p53 and complete response among rectal cancer patients treated with neoadjuvant radiation-based therapy.](pone.0045388.g003){#pone-0045388-g003}

![Forest plots of RR were assessed for association between p53 and poor response among rectal cancer patients treated with neoadjuvant radiation-based therapy.](pone.0045388.g004){#pone-0045388-g004}

Data Extraction and Definitions {#s2c}
-------------------------------

According to the inclusion criteria listed above, the following data were extracted for each study: the first author's surname, publication year, country of origin, number of patients analyzed, treatment, types of measurement and over expression of TP53 protein and/or TP53 gene mutation frequency. Data on the main outcomes were entered in tables showing the pathological responses to radiation-based therapy with respect to p53 status. Information was carefully and independently extracted from all eligible publications by two of the authors (Chen and Wu). Any disagreement between the researchers was resolved by discussions until a consensus was reached. If they failed to reach a consensus, a third investigator (Lu) was consulted to resolve the dispute.

10.1371/journal.pone.0045388.t003

###### Risk ratio for the association between wild-type form of TP53 and the response to neoadjuvant radiation-based radiotherapy.
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  comparison             complete response    good response     poor response                                                                                  
  --------------------- ------------------- ------------------ --------------- ------- ---- ------------------ ------- ------- ---- ------------------ ------- -------
  all studies                   10           1.65(1.19--2.30)       0.003       0.478   28   1.30(1.14--1.49)   0.000   0.628   24   0.85(0.75--0.96)   0.007   0.949
  treatment                                                                                                                                                    
  RT                             3           2.80(0.88--8.86)       0.081       0.764   7    1.90(1.44--2.51)   0.000   0.386   8    0.81(0.69--0.94)   0.007   0.783
  CRT                            6           1.92(1.26--2.91)       0.002       0.673   14   1.20(1.01--1.43)   0.043   0.860   12   0.87(0.68--1.12)   0.284   0.790
  type of measurement                                                                                                                                          
  protein                        7           1.35(0.92--1.98)       0.124       0.562   23   1.18(1.02--1.36)   0.025   0.501   19   0.91(0.79--1.05)   0.191   0.729
  gene                           3           2.78(1.40--5.50)       0.003       0.909   7    1.48(1.15--1.91)   0.002   0.443   7    0.79(0.64--0.98)   0.033   0.994

Subgroup analysis was performed when at least two studies were in each subgroup.

N, number of studies; Ph, p value of Q-test for heterogeneity.

Two studies [@pone.0045388-Elsaleh1], [@pone.0045388-LopezCrapez1] employed both protein and gene detection, we used the gene detection data, but also examined the protein detection data, and found similar results (data not shown).

One study [@pone.0045388-Suzuki1] diagnosed complete response according to two criteria (JSCCR and Mandard AM), we used the data according to Mandard AM, but also examined the data according to JSCCR, and found similar results (data not shown).

![The funnel plot shows that there was no obvious indication of publication bias for the outcome of good response setting.](pone.0045388.g005){#pone-0045388-g005}

We used the definitions and standardizations for 'p53' and 'response to radiation-based therapy'. For consistency, we used 'p53 status' to refer to both the gene and protein markers. Wild-type form of p53 status means patients with low expression of p53 protein and/or wild-type p53 gene. Pathologic response after neoadjuvant radiation-based therapy in different studies were according to different tumor regression grade (TRG) systems, most of the studies used TRG system described by Dworak et al. [@pone.0045388-Dworak1] and Rodel et al. [@pone.0045388-Rodel1], which categorize tumour regression in four grades, and TRG 2 and 3 determination is semiquantitatively defined as more/less than 50% tumour regression, respectively. Other grading systems have been proposed to categorize tumour regression in three grades where intermediate responders are grouped [@pone.0045388-Therasse1]. For consistency, we defined the pathologic response classification in the [table 1](#pone-0045388-t001){ref-type="table"}. Briefly, poor response (residual tumor rate ≥75%); good response (residual tumor rate \<50%); complete response (residual tumor rate = 0%).

Statistical Analysis {#s2d}
--------------------

RR with 95% CIs was used to estimate the association between p53 status and response to neoadjuvant radiation-based therapy in rectal cancer patients. Subgroup analyses were performed to evaluate the effects of different treatment regimens (CRT and RT) and different methods of p53 gene determination (protein and gene). The presence of statistical heterogeneity was assessed with Cochran's Q test (considered significant for Ph\<0.10). The pooled RR was calculated using a fixed-effects model (the Mantel--Haenszel method) or a random-effects model (the DerSimonian and Laird method), according to the heterogeneity. Funnel plots and the Egger's test were employed to estimate the possible publication bias. We also performed sensitivity analysis by omitting each study or specific studies to find potential outliers. Statistical analyses were conducted using Stata (version SE/10; StataCorp, College Station, TX). p values for all comparisons were two-tailed and statistical significance was defined as p\<0.05 for all tests, except those for heterogeneity.

Results {#s3}
=======

Eligible Studies {#s3a}
----------------

A total of 467 articles were retrieved by a literature search of the PubMed, Embase, and Web of Science databases, using different combinations of key terms. As indicated in the search flow diagram ([Figure 1](#pone-0045388-g001){ref-type="fig"}), 30 studies [@pone.0045388-Shinto1]--[@pone.0045388-Brophy1], [@pone.0045388-Kandioler1]--[@pone.0045388-Fu1], [@pone.0045388-Elsaleh1], [@pone.0045388-Kelley1], [@pone.0045388-Moral1]--[@pone.0045388-Spitz2] reported at least one of the outcomes of interest and were finally included in the meta-analysis. The characteristics of the eligible studies are summarized in [Table 2](#pone-0045388-t002){ref-type="table"}. Eighteen used neoadjuvant CRT and six used neoadjuvant RT, while five include both CRT and RT ([Table 2](#pone-0045388-t002){ref-type="table"}), Twenty-five of the studies employed protein detection (including immunohistochemistry), seven employed gene detection (including genomic sequencing, Polymerase Chain Reaction-Single Strand Conformation Polymorphism\[PCR-SSCP\] etc.), two employed both methods ([Table 2](#pone-0045388-t002){ref-type="table"}). The sample sizes in all the eligible studies ranged from 22--111 patients (median = 58 patients, mean = 61 patients, standard deviation \[SD\] = 4.73). Overall, the eligible studies included 1,830 patients. Eighteen of the studies were conducted in European or North American populations with mixed but mostly white participants (1,127 patients), whereas ten were conducted in East Asian populations (703 patients).

Evidence Synthesis {#s3b}
------------------

Among the studies of rectal cancer patients who received neoadjuvant radiation-based therapy, 28 studies involving 1,769 patients contributed data on good response setting. Wild-type form of p53 status was significantly associated with improved good response among patients treated with neoadjuvant radiation-based therapy (RR = 1.30; 95% CI = 1.14--1.49; p\<0.001, [Figure 2](#pone-0045388-g002){ref-type="fig"}). Ten studies involving 646 patients contributed data on complete response setting. Wild-type form of p53 status was significantly associated with improved complete response (RR = 1.65; 95% CI = 1.19--2.30; p = 0.003, [Figure 3](#pone-0045388-g003){ref-type="fig"}). Finally, 24 studies involving 1,478 patients provided information on poor response setting. Wild-type form of p53 status was significantly associated with decreases in poor response setting (RR = 0.85; 95% CI = 0.75--0.96; p = 0.007, [Figure 4](#pone-0045388-g004){ref-type="fig"}).

Subgroup Analysis {#s3c}
-----------------

Among the 30 studies in the neoadjuvant subgroup, 18 used neoadjuvant CRT and six used neoadjuvant RT, while five include both CRT and RT ([Table 3](#pone-0045388-t003){ref-type="table"}). The results of the neoadjuvant CRT and RT were therefore calculated separately. Wild-type form of p53 status was associated with improved response in rectal cancer patients who received neoadjuvant CRT (good response: RR = 1.20, 95% CI = 1.01--1.43, p = 0.043, complete response: RR = 1.92, 95% CI = 1.26--2.91, p = 0.002), but not with poor response (RR = 0.91, 95% CI = 0.68--1.12, p = 0.284). Wild-type form of p53 status was associated with good response in neoadjuvant RT settings (RR = 1.90, 95% CI = 1.44--2.51, p\<0.001), and with decreased poor response (RR = 0.81; 95% CI = 0.69--0.94; p = 0.007), but not with complete response(RR = 2.80, 95% CI = 0.88--8.86, p = 0.081).

Different measurements of p53 status (either by protein or gene detection) have been used to evaluate associations with favorable responses to neoadjuvant radiation-based therapy. We therefore calculated the associations using both protein and gene statuses of p53. The results of subgroup analysis are presented in [Table 3](#pone-0045388-t003){ref-type="table"}. For gene detection, wild-type p53 gene was significantly associated with increased response (good response: RR = 1.48, 95% CI = 1.15--1.91, p = 0.002, complete response: RR = 2.78, 95% CI = 1.40--5.50, p = 0.003), and with decreased Poor response (RR = 0.79; 95% CI = 0.64--0.98; p = 0.033) among patients treated with neoadjuvant therapy. For protein-based detection, low expression of p53 protein was significantly associated with increased good response (RR = 1.18, 95% CI = 1.02--1.36, p = 0.025) among patients treated with neoadjuvant therapy, but not with complete response (RR = 1.35; 95% CI = 0.92--1.98; p = 0.124) and poor response (RR = 0.91; 95% CI = 0.79--1.05; p = 0.191).

Publication Bias {#s3d}
----------------

Begg's funnel plot and Egger's test were used to estimate the publication bias of the included literature. The shapes of the funnel plots showed no evidence of obvious asymmetry ([Figure 5](#pone-0045388-g005){ref-type="fig"}), and Egger's test indicated the absence of publication bias (p\>0.05). Moreover, sensitivity analysis was carried out to assess the influence of individual studies on the summary effect. No individual study dominated this meta-analysis, and the removal of any single study had no significant effect on the overall results (data not shown).

Discussion {#s4}
==========

The p53 status had been shown to play a pivotal role in the response to radiation-based therapy [@pone.0045388-Huerta1], [@pone.0045388-Smith1]. Previous studies suggested that rectal cancers with p53 mutations might be either resistant or sensitive to neoadjuvant radiation-based therapy. However, the issue could not be resolved, because most of the available clinical reports involved small sample sizes, and the results were therefore unable to determine the value of p53 status for predicting the response to neoadjuvant radiation-based therapy. We therefore concluded that a meta-analysis was the best way of evaluating the association between p53 status and response to neoadjuvant radiation-based therapy in a large population.

The current meta-analysis of 30 studies systematically evaluated the association between p53 status and response to neoadjuvant radiation-based therapy in a large population. The results indicate that wild-type form of p53 status may predict good response rates to neoadjuvant therapy in patients with rectal cancer. Wild-type form of p53 status was associated with improved good and complete response, decreased poor response. Stratification according to different treatments showed that this association remained for sub-groups of good and poor response in RT, good and complete response in CRT, except for poor response in CRT and complete response in RT. Further stratification by gene detection revealed imprecise results, but amplification of the wild-type p53 gene was also associated with relevant increases in good and complete response, decreased poor response; however, although low expression of p53 was associated with relevant increases in good resonse, it was not associated with complete response and poor response. Gene detection was associated with advantages regarding response rates to neoadjuvant radiation-based therapy in patients with rectal cancer. The current meta-analysis suggests that p53 status as an independent predictive factor for neoadjuvant radiation-based therapy outcome in patients with rectal cancer, and gene detection may be a better assay to use in the evaluation of p53 status and sensitivity to neoadjuvant radiation-based therapy. Radiosensitive tumors could be identified by the detection of p53 status, a selective and individualized form of chemoradiation might be instituted. Novel molecular treatment strategies specifically designed to reactivate p53 within resistant tumors can be used as combined modality protocols to improve local response rate [@pone.0045388-Cuddihy1].

In interpreting our results of the current meta-analysis, some limitations need to be addressed. First, the meta-analysis may have been influenced by publication bias; although we tried to identify all relevant data and retrieve additional unpublished information, some missing data were unavoidable. Second, the studies used different measurements of p53 status (either protein or gene detection), and different tumor regression grade systems. Standardization is therefore of great importance for obtaining an accurate assessment of the clinical significance of p53 status. Although we made considerable efforts to standardize definitions, some variability in definitions of methods, measurements, and outcomes among studies was inevitable, which may lead to a misclassification bias. Third, Different measurements of p53 status (either byIHC or by DNA sequencing techniques) have been employed to evaluate association with favorable response to neoadjuvant radiation-based therapy. Cut-off values of p53 for both overexpression by IHC and gene amplification by PCR were not the same in each study, which might lead to inconsistent results between these studies. Therefore, standardization is particularly important when assessing p53 status (gene and protein), which will help to obtain accurate data with clinical significance. Fourth, our analysis was observational in nature, and we therefore cannot exclude confounding as a potential explanation of the observed results. Despite these limitations, this meta-analysis had several advantages. First, a large number of cases were pooled from different studies, and 1,830 subjects represent a sizeable number, significantly increasing the statistical power of the analysis. Secondly, no publication biases were detected, indicating that the pooled results may be unbiased.

This study is the first meta-analysis to assess the usefulness of p53 status for predicting the response of rectal cancer patients to neoadjuvant radiation-based therapy. Our data support p53 status as a useful predictive factor for assessing treatment response to neoadjuvant radiation-based therapy in rectal cancer patients. However, future studies with larger sample sizes, more advanced and accurate detection methods and more comprehensive study designs are required to confirm our finding.
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